Do ARKG and PBE hold the same stocks?

By their latest filings, 12% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, ARKG or PBE?

ARKG has 5% of its weight in S&P 500 names and PBE has 32%, so PBE differs more from the index.

Which is cheaper, ARKG or PBE?

ARKG charges 0.75% a year and PBE charges 0.59%, so PBE is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

ARKG vs PBE: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, ARKG returned +68.4% to PBE's +44.2%; 12% of their weight is in the same names.

askIQ about this page

askIQ about ARKG and PBE

Net assets: $2.1bn on Nov 2, 2026 for ARK Genomic Revolution ETF, and $442m on Nov 3, 2026 for Invesco Biotechnology & Genome ETF.

ARKG on its own →PBE on its own →

At a glance

4.6%

ARKG in the S&P 500

32.3%

PBE in the S&P 500

+68.4%

ARKG total return, 1 year

+44.2%

PBE total return, 1 year

ARKG · 1 year to Nov 4, 2026 95% of its weight is outside the S&P 500

5% of ARKG's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 2, 2026.

PBE · 1 year to Nov 4, 2026 68% of its weight is outside the S&P 500

32% of PBE's weight is in S&P 500 companies and 68% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

PBE costs 0.16 points a year less; their one-year returns differ by 24.2 points; ARKG is 4.8 times larger.

ARKG vs PBE: Holdings Overlap & Returns
Measure	ARKG	PBE
Return
Measure	ARKG	PBE
Total return, 1 year	+68.4%	+44.2%
Drawdown
Measure	ARKG	PBE
Below its all-time high	55.5%, high on Jan 20, 2021
Benchmark
Measure	ARKG	PBE
What it tracks	Genomics and gene editing	Biotech
Cost and size
Measure	ARKG	PBE
Expense ratio	0.75%	0.59%
Net assets, as of Nov 2, 2026	$2.1bn	$435m
Active share vs the S&P 500	98%	99%
Holdings
Measure	ARKG	PBE
Holdings in common	12%
Top ten holdings, share of the fund	58%	49%

Method

Risk and return

Nov 7, 2014 to Oct 30, 2026 · 625 weekly returns

ARKG PBE

Return

Total return edge ARKG +179.6% +120.5%

Annualized edge ARKG +8.9% +6.8%

Price return edge ARKG +161.6% +111.1%

Risk

Volatility edge PBE 39.8% 24.8%

Max drawdown edge PBE −82.9% −42.4%

Risk-adjusted

Sharpe edge ARKG 0.36 0.30

Sortino edge ARKG 0.55 0.44

Calmar edge PBE 0.11 0.16

Reading

From Nov 2014 to Oct 2026, ARKG returned more: +179.6% to +120.5%. PBE swung less: 24.8% to 39.8%. PBE fell less at its worst: −42.4% to −82.9%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: ARKG vs PBE: Holdings Overlap & Returns
Measure	ARKG	PBE	Edge	How it is measured
Return
Total return	+179.6%	+120.5%	ARKG	Price change plus distributions, reinvested.
Annualized	+8.9%	+6.8%	ARKG	Total return as a yearly rate.
Price return	+161.6%	+111.1%	ARKG	Price change alone, distributions left out.
Risk
Volatility	39.8%	24.8%	PBE	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	26.2%	17.1%	PBE	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−82.9%	−42.4%	PBE	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.36	0.30	ARKG	Return above Treasury bills per unit of volatility.
Sortino	0.55	0.44	ARKG	Return above Treasury bills per unit of downside deviation.
Calmar	0.11	0.16	PBE	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 625 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

12%

By the books each fund has filed, ARKG and PBE hold 12% of their money in the same securities at the same weight. Holdings dated Nov 2, 2026 and Nov 3, 2026.

50%

0 half 100%

half

12% in common

Positions both hold · largest shared weight first ARKG PBE

NATERA INC 4.67% 5.56%

ILLUMINA INC 4.26% 5.10%

VERACYTE INC 3.80% 3.00%

Only in one fund ↓

Only in ARKG

TEMPUS AI INC-CL A 9.85%

10X GENOMICS INC-CLASS A 7.52%

TWIST BIOSCIENCE CORP 7.42%

CRISPR THERAPEUTICS AG 5.48%

GUARDANT HEALTH INC 5.13%

ABSCI CORP 5.08%

ELI LILLY & CO 4.59%

CAREDX INC 4.50%

Only in PBE

Regeneron Pharmaceuticals Inc 5.62%

Biogen Inc 5.43%

Gilead Sciences Inc 5.42%

Royalty Pharma PLC 5.15%

Amgen Inc 5.02%

Vertex Pharmaceuticals Inc 4.62%

Moderna Inc 3.78%

Exelixis Inc 3.35%

Check overlap with more funds →

Window by window

Window by window: ARKG vs PBE: Holdings Overlap & Returns
	Total return
Window	ARKG	PBE
3 months	+20.5%	+14.2%
6 months	+60.0%	+27.1%
1 year	+68.4%	+44.2%
3 years	+90.8%	+90.4%
Since launchNot the same days: ARKG Oct 2014 · PBE Jun 2005	+164.2%	+650.5%

Open this comparison in the app →

Side by side

ARKG ARK Genomic Revolution ETF · Holds 35 stocks in genomics and gene editing, 5% of its weight in S&P 500 companies PBE Invesco Biotechnology & Genome ETF · Holds 32 stocks in biotech, 32% of its weight in S&P 500 companies

Issuer ARK Invesco

Theme Genomics and gene editing Biotech

In the S&P 500 4.6% 32.3%

Active share vs the S&P 500 98.5% 99.0%

In the Nasdaq-100 0.0% 20.7%

Holdings 35 32

Top ten, share of the fund 58.5% 49.1%

Expense ratio 0.75% 0.59%

Fee for the differing part 0.76% 0.60%

Total return, 1 year +68.4% +44.2%

vs its benchmark not measured not measured

Below its high −55.5% 0.0%

Net assets, ARKG as of Nov 2, 2026 and PBE as of Nov 3, 2026 $2.1bn $442m

As of Nov 4, 2026. Source: ETFIQ.

12% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

ARKG

By weight, 5% of ARKG's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 58% of the fund across 35 positions, as published by its issuer for Nov 2, 2026. Over the year to Nov 4, 2026 the fund returned +68.4% with distributions reinvested. It sits 55.5% below its all-time high of Jan 20, 2021.

PBE

By weight, 32% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 49% of the fund across 32 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +44.2% with distributions reinvested.

Questions people ask

Do ARKG and PBE hold the same stocks?: By their latest filings, 12% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, ARKG or PBE?: ARKG has 5% of its weight in S&P 500 names and PBE has 32%, so PBE differs more from the index.
Which is cheaper, ARKG or PBE?: ARKG charges 0.75% a year and PBE charges 0.59%, so PBE is cheaper. Fees come from each fund's prospectus.

Other comparisons

ARKG vs IBBQ ARKG vs FBT ARKG vs XBI ARKG vs IBB PBE vs IDNA PBE vs GNOM PBE vs GNMX PBE vs PBPH

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →ARKG on its own →PBE on its own →ARKG holdings →PBE dividend history →PBE holdings →Method →Standards and sources →

Sources and dates

ARKG filings on SEC EDGAR ↗

ARKG prospectus with the expense ratio (SEC) ↗

ARK page for ARKG ↗

PBE filings on SEC EDGAR ↗

PBE prospectus with the expense ratio (SEC) ↗

Invesco page for PBE ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, ARKG against PBE, data as of Nov 4, 2026. https://etfiq.com/compare/themes/arkg-vs-pbe

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.